| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 2
Neuroprotective effects of aminophylline in LPS-induced Alzheimer"s disease in rat model
1 Al-Nahrain University, College of Pharmacy, Department of Pharmacology, Baghdad, Iraq2 University of Warith Al-Anbiyaa, College of Medicine, Department of Pharmacology, Karbala, Iraq
DOI : 10.23893/1307-2080.APS6318 Viewed : 79 - Downloaded : 26 This research aimed to evaluate the aminophylline neuroprotective benefits against Alzheimer"s Disease -like characteristics caused by lipopolysaccharide (LPS) in forty rats divided into four groups: control group, induction group received lipopolysaccharide single dose once a day for seven days, third group received donepezil orally once daily for 21 days and fourth groups received aminophylline once daily for 21 days, and both third and fourth group received LPS once. The Barnes Maze behavioral parameters evaluated, inflammatory cytokines, and oxidative stress indicators were measured in brain tissue samples and the results showed that primary latency and primary error for the three phases of Barnes Maze behavioral test and the levels of studied inflammatory cytokines (IL-1b, IL-6, and TNFa) in addition to malondialdehyde (MDA) were reduced significantly in aminophylline group comparing with induction group while SOD1 levels increased significantly in aminophylline group comparing with induction group which indicate that aminophylline has neuroprotective effects via antioxidant and anti-inflammatory properties. Keywords : neuroprotective effects, aminophylline, LPS-induced Alzheimer"s disease